2024
Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221
Chen C, Zirpoli G, Budd G, Barlow W, Pusztai L, Hortobagyi G, Albain K, Godwin A, Thompson A, Henry N, Ambrosone C, Stringer K, Hertz D. Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221. Cancer Chemotherapy And Pharmacology 2024, 94: 311-321. PMID: 38814343, DOI: 10.1007/s00280-024-04680-6.Peer-Reviewed Original ResearchCIPN severityPeripheral neuropathyPaclitaxel-induced peripheral neuropathyEarly-stage breast cancerTrial of patientsBackgroundChemotherapy-induced peripheral neuropathyBody mass indexSerum amino acid concentrationsOver-representation analysisDebilitating neurotoxicityPaclitaxel scheduleAnti-cancer agentsBreast cancerSelf-reported raceMass indexMetabolic pathways of amino acidsSerum concentrationsInverse associationAmino acid metabolic pathwaysPaclitaxelPrimary analysisBonferroni correctionTreatment limitationsS0221CIPN
2022
Vitamin D insufficiency as a peripheral neuropathy risk factor in white and black patients in SWOG 0221.
Chen C, Zirpoli G, McCann S, Barlow W, Budd G, Pusztai L, Hortobagyi G, Godwin A, Thompson A, Ambrosone C, Stringer K, Hertz D. Vitamin D insufficiency as a peripheral neuropathy risk factor in white and black patients in SWOG 0221. Journal Of Clinical Oncology 2022, 40: 12023-12023. DOI: 10.1200/jco.2022.40.16_suppl.12023.Peer-Reviewed Original ResearchVitamin D insufficiencyPaclitaxel-induced peripheral neuropathyD insufficiencyPeripheral neuropathyBlack patientsPaclitaxel scheduleIncrease riskHigh riskEarly-stage breast cancerNeuropathy risk factorsPaclitaxel-containing chemotherapyVitamin D supplementationSensory peripheral neuropathyTreatment-limiting toxicityBody mass indexRetrospective validation studySelf-reported raceD supplementationProspective trialWhite patientsFemale patientsMass indexBlack raceRisk factorsTreatment outcomes